Literature DB >> 12748306

An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors.

Kate A Scott1, Robert J Moore, Caroline H Arnott, Nick East, Richard G Thompson, Bernard J Scallon, David J Shealy, Frances R Balkwill.   

Abstract

The proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) was originally considered to have activity against malignant disease. However, recent studies suggest TNF-alpha may also act as an endogenous tumor promoter. In the present work, mice deficient in TNF-alpha either genetically (TNF-alpha(-/-)) or after blockade with a neutralizing antibody (cV1q) were used to investigate the role of TNF-alpha in skin tumor development. Papillomas were induced in wild-type (wt) mice after treatment of skin with the initiating agent 9,10-dimethyl-1,2-benzanthracene followed by promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA) for 15 weeks. TNF-alpha(-/-) mice were resistant to papilloma development when compared with wt mice on C57Bl/6J, 129/SvEv, and BALB/c genetic backgrounds. Primary murine keratinocytes (newborn keratinocytes) and skin homogenates were used to characterize TPA-stimulated TNF-alpha expression. TPA induced TNF-alpha protein in newborn keratinocytes in vitro and epidermis in vivo. Neutralization of TNF-alpha protein with cV1q in vivo for 0-15 weeks of promotion significantly decreased skin tumor development after 9,10-dimethyl-1,2-benzanthracene/TPA treatment. cV1q treatment during the early stages of tumor promotion (0-6 weeks) was equally effective. These data suggest that early induction of TNF-alpha is critical for skin tumor promotion. cV1q also reduced TPA-stimulated expression of matrix metalloproteinase 9 and granulocyte macrophage colony-stimulating factor, proteins that are differentially regulated in wt and TNF-alpha(-/-) epidermis. Treatment of the 410.4 transplantable breast carcinoma with cV1q reduced tumor growth in vivo, illustrating that inhibition of tumor growth through neutralization of TNF-alpha is not limited to skin carcinogenesis. These results provide further evidence for procancer actions of TNF-alpha and give some rationale for use of TNF-alpha antagonists in cancer prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748306

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  45 in total

1.  Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis.

Authors:  Sabina Sangaletti; Claudio Tripodo; Chiara Ratti; Silvia Piconese; Rossana Porcasi; Rosalba Salcedo; Giorgio Trinchieri; Mario P Colombo; Claudia Chiodoni
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 2.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  TNFα enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells.

Authors:  Sung Hee Lee; Hannah S Hong; Zi Xiao Liu; Reuben H Kim; Mo K Kang; No-Hee Park; Ki-Hyuk Shin
Journal:  Biochem Biophys Res Commun       Date:  2012-06-20       Impact factor: 3.575

4.  Instantaneous depolarization of T cells via dopamine receptors, and inhibition of activated T cells of Psoriasis patients and inflamed human skin, by D1-like receptor agonist: Fenoldopam.

Authors:  Aviad Keren; Amos Gilhar; Yehuda Ullmann; Marina Zlotkin-Frušić; Yoram Soroka; Abraham J Domb; Mia Levite
Journal:  Immunology       Date:  2019-11       Impact factor: 7.397

Review 5.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

6.  TNF signaling drives myeloid-derived suppressor cell accumulation.

Authors:  Xueqiang Zhao; Lijie Rong; Xiaopu Zhao; Xiao Li; Xiaoman Liu; Jingjing Deng; Hao Wu; Xia Xu; Ulrike Erben; Peihua Wu; Uta Syrbe; Joachim Sieper; Zhihai Qin
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

7.  Female temperament, tumor development and life span: relation to glucocorticoid and tumor necrosis factor alpha levels in rats.

Authors:  Sonia A Cavigelli; Jeanette M Bennett; Kerry C Michael; Laura Cousino Klein
Journal:  Brain Behav Immun       Date:  2007-12-21       Impact factor: 7.217

8.  Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice.

Authors:  Annika Jögi; Birgitte Rønø; Ida K Lund; Boye S Nielsen; Michael Ploug; Gunilla Høyer-Hansen; John Rømer; Leif R Lund
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

9.  Myeloid-derived suppressor cells promote B-cell production of IgA in a TNFR2-dependent manner.

Authors:  Xia Xu; Qinghong Meng; Ulrike Erben; Peigang Wang; Rainer Glauben; Anja A Kühl; Hao Wu; Chung Wah Ma; Minghua Hu; Yuanyuan Wang; Wei Sun; Junying Jia; Xinyi Wu; Wei Chen; Britta Siegmund; Zhihai Qin
Journal:  Cell Mol Immunol       Date:  2016-05-02       Impact factor: 11.530

10.  Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.

Authors:  Doris M Benbrook; Stan Lightfoot; James Ranger-Moore; Tongzu Liu; Shylet Chengedza; William L Berry; Igor Dozmorov
Journal:  Gene Regul Syst Bio       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.